Invention Grant
- Patent Title: LRFFT2 cell
-
Application No.: US16508740Application Date: 2019-07-11
-
Publication No.: US11718827B2Publication Date: 2023-08-08
- Inventor: Shunchang Jiao , Rong Zhang , Tianfu Zhang , Zishan Zhou , Jiasen Xie , Ziming Wu , Gang Peng
- Applicant: BEIJING DCTY BIOTECH CO., LTD. , Shunchang Jiao
- Applicant Address: CN Beijing
- Assignee: Beijing DCTY Biotech Co., Ltd.,Shunchang Jiao
- Current Assignee: Beijing DCTY Biotech Co., Ltd.,Shunchang Jiao
- Current Assignee Address: CN Beijing; CN Beijing
- Agency: Avek IP, LLC
- Priority: CN 1811153257.5 2018.09.30
- Main IPC: C12N15/85
- IPC: C12N15/85 ; C12N5/0783 ; C07K14/725 ; C12N7/00 ; C12N15/11 ; C12N15/86 ; G01N33/50

Abstract:
Some embodiments of the disclosure use human peripheral blood for ctDNA sequencing or tumor tissues for whole exome sequencing, screen out mutation sites to perform antigen epitope prediction, connect and synthesize an expression gene sequence of mutant peptides. Other embodiments of the disclosure construct a lentiviral vector, package the lentivirus, transfect an APC cell to complete transformation of a specific LV cell, co-culture in vitro with PBMC separated from the peripheral blood, screen out an effective polypeptide, and transform common T cells into RFF cells. Suppressive signaling molecules include one or more of PD-1, Tim-3, LAG3, CTLA-4, BTLA, VISTA, CD160, and 2B4 (CD244). Antigen presenting cells include one or more of PBMC, a dendritic cell, neutrophil, B lymphocyte, and macrophage.
Information query
IPC分类: